Patent application number | Description | Published |
20090184533 | Vehicle Endgate Hinge Assembly - A vehicle endgate hinge assembly is disclosed. The hinge assembly has a bodyside hinge strap including a hinge support boss extending through the endgate opening shut-face and having a central hole that is coaxial with the endgate pivot axis, a mounting plate located outboard of the shut-face, and a threaded portion extending from the mounting plate through the shut-face. The hinge assembly may have a crank including a hinge key pivotally coupled to a member mounted on the endgate, a pivot shaft extending from the hinge key through the central hole, a lever arm extending from the pivot shaft normal to the endgate pivot axis, and a ball extending from the lever arm spaced from the endgate pivot axis. A nut is located inboard of the endgate opening shut-face and threadably received on the threaded portion, and an energy storage mechanism is coupled to the ball. | 07-23-2009 |
20100084885 | Viscous Rotary Damper for Vehicle End Gate Assembly - A viscous rotary damping device for a vehicle end gate assembly is provided. The damping device includes a housing member configured to operatively attach to the vehicle body or the end gate assembly. The housing member defines a fluid chamber having viscous fluid therein. The damping device also includes an impeller member having a mast with a first end configured to operatively attach to the other of the vehicle body and the end gate assembly, and a second end having one or more blades projecting outward therefrom. The second end of the mast is rotatably received in the fluid chamber such that the impeller member dissipates kinetic energy generated by the end gate assembly when transitioning between a first, closed position and a second, open position. A cover plate member is preferably coupled to the housing member, and configured to fluidly seal the fluid chamber. | 04-08-2010 |
20130263407 | DECKLID HINGE COUNTERBALANCE SYSTEM WITH A COMBINATION TORQUE ROD AND TORQUE TUBE ASSEMBLY - A decklid hinge assembly for a vehicle includes a counterbalance torque system having a torque storing assembly. The torque storing assembly includes a torque rod having a first axial end and a second axial end, and a torque tube having a first axial end and a second axial end. The first axial end of the torque rod is attached to a linkage system in torque transmitting engagement for transmitting torque therebetween, the second axial end of the torque rod is attached to the second axial end of the torque tube in torque transmitting engagement for transmitting torque therebetween, and the first axial end of the torque tube is attached to a hinge box in torque transmitting engagement for transmitting torque therebetween. The torque storing assembly is pre-loaded with a moment to generate a torque for assisting movement of the support member from a closed position into an open position. | 10-10-2013 |
20140290007 | DECKLID HINGE ASSEMBLY FOR A VEHICLE - A hinge assembly includes a hinge box, and a decklid attachment bracket rotatably attached to the hinge box. The decklid attachment bracket includes a contoured surface. A compressible member is positioned for engagement with the contoured surface as the decklid attachment bracket moves between an open position and a closed position. The contoured surface defines an outer region, a recessed region, and an inner region. The outer region compresses the compressible member as the decklid attachment bracket moves between the open and closed positions to absorb energy and dampen movement of the decklid attachment bracket. The recessed region cradles the compressible member without substantially compressing the compressible member when the decklid attachment bracket is in the open position to secure the position of the decklid attachment bracket. The inner region compresses the compressible member to absorb energy, and limit movement of the decklid attachment bracket beyond the open position. | 10-02-2014 |
20140333087 | VEHICLE AND A HINGE ASSEMBLY FOR A STORAGE COMPARTMENT OF THE VEHICLE - A vehicle and a hinge assembly for a storage compartment of the vehicle are disclosed. The hinge assembly includes a first component and a second component coupled to the first component. The second component is movable between a first position and a second position relative to the first component. A damper device includes a housing assembly supported by the first component and a finger attached to the second component such that the finger is movable with the second component between the first and second positions. The finger and the housing assembly are spaced from each other when the second component is in the first position, and the finger slidingly engages the housing assembly as the second component moves to the second position such that frictional engagement between the finger and the housing assembly dampens movement of the second component relative to the first component. | 11-13-2014 |
Patent application number | Description | Published |
20100130595 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 05-27-2010 |
20110172296 | MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION - Provided are compounds capable of inhibiting expression of TGF-beta 1 and compositions containing same as well as methods using such compounds for treating fibrotic diseases including the reduction of scarring resulting from wound healing. | 07-14-2011 |
20110213011 | MODULATION OF SMAD3 EXPRESSION - Provided are compounds capable of inhibiting SMAD3 and compositions containing same as well as methods using such compounds for treating fibrosis and scarring. | 09-01-2011 |
20120238937 | METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF) - This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described. | 09-20-2012 |
20130190380 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 07-25-2013 |
20130190382 | METHODS FOR INHIBITING EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 07-25-2013 |
20150376623 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 12-31-2015 |
Patent application number | Description | Published |
20080207921 | Organic Compounds - The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula III, | 08-28-2008 |
20090018325 | PROCESS FOR PREPARING L-NUCLEIC ACID DERIVATIVES AND INTERMEDIATES THEREOF - A novel method has been found to produce 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now, is possible. | 01-15-2009 |
20100168229 | Process for the preparation of optically active compounds using transfer hydrogenation - A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate. | 07-01-2010 |
20100274027 | ORGANIC COMPOUNDS - The invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Allskiren. Inter alia, the invention provides a process for the manufacture of a compound of the formula III, | 10-28-2010 |
20130096337 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation - A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate. | 04-18-2013 |